AI clinical diagnostic company Renalytix AI plc (LON:RENX) reported on Thursday the receipt of the US Food and Drug Administration's (FDA) Breakthrough Device designation for its lead AI-enabled diagnostic for kidney disease, KidneyIntelX.
According to Renalytix, this is the first such designation for an AI-enabled diagnostic for kidney disease publicly announced by any company. KidneyIntelX is being developed in close collaboration with the Mount Sinai Health System.
The KidneyIntelX is designed to diagnose and improve clinical management of patients with Type II diabetes with fast-progressing kidney disease, in an effort to curtail the estimated USD114bn annual cost of chronic and end-stage kidney disease to the United States healthcare system.
The KidneyIntelX diagnostic will use machine learning algorithms to assess the combination of predictive blood-based biomarkers, including sTNFR1, sTNFR2 and KIM1, in combination with electronic health record information, to identify progressive kidney disease.
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Nanomi BV to acquire ophthalmology specialist VISUfarma BV
AstraZeneca launches online platform to expand patient access to medications
Avant Technologies enters joint venture to advance stem cell-based diabetes treatments
Innovent and Ollin report progress in development of OLN324 (IBI324)
Alteogen secures European Commission approval for aflibercept biosimilar EYLUXVI
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Ascletis presents ASC30 study results at EASD Annual Meeting
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation